Blockbuster to be? Novartis snags a major win as FDA OKs a top PhIII drug -- will a pricing controversy follow?
After racking up a large batch of positive data demonstrating its ability to slow the rate of disease progression, Novartis today toasted an FDA approval of their S1P multiple sclerosis drug siponimod, soon to hit the market as Mayzent.
By most accounts, this is a blockbuster to be. And it also could be a blockbuster killer.
EvaluatePharma pegged 2024 sales of this drug at $1.3 billion, making it an important part of Novartis’ late-stage pipeline and a checkmark in the win column for development chief John Tsai and CEO Vas Narasimhan, who handed him the job when Narasimhan moved up in the world.
Basic subscription required
Unlock this story instantly and join 57,400+ biopharma pros reading Endpoints daily — and it's free.